Atossa Therapeutics (ATOS) Short-Term Debt issuances (2012)
Atossa Therapeutics (ATOS) posted quarterly Short-Term Debt issuances of -$250000.0 for Q4 2012, up 66.67% quarter-over-quarter from -$750000.0 in Q1 2012.
Atossa Therapeutics (ATOS) Short-Term Debt issuances (2012) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Short-Term Debt issuances for 1 consecutive years, with -$250000.0 the latest figure, recorded in Q4 2012.
- In Q4 2012, Short-Term Debt issuances changed N/A year-over-year to -$250000.0; the TTM figure through Sep 2013 stood at -$250000.0 (up 66.67% YoY), while the FY2012 annual figure was -$1.0 million, down 200.0% from the prior year.
- Short-Term Debt issuances improved to -$250000.0 in Q4 2012 per ATOS's latest filing, from -$750000.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at -$250000.0 in Q4 2012 and bottomed at -$750000.0 in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -250,000.00 |
| Dec 31, 2012 | -250,000.00 |
| Mar 31, 2012 | -750,000.00 |
| Mar 31, 2012 | -750,000.00 |